Drug intelligence / Profile preview

ALVAC gp100 vaccine

Development stage: Unknown
Lead developer: Sanofi Pasteur
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intranodal, Subcutaneous

Overview

A therapeutic cancer vaccine composed of a replication-defective plaque purified recombinant canarypox virus (ALVAC) that encodes the glycoprotein 100 (gp100) gene. The vaccine is designed to stimulate the immune system to recognize and attack cancer cells expressing the gp100 antigen, particularly in melanoma. It has been studied using various administration routes, including intranodal injections, which have shown to be feasible, safe, and potentially superior to subcutaneous administration.

Other names: ALVAC-GP-100 vaccineALVAC-GP100 vaccineALVAC-GP 100 vaccine

Targets

PMEL (Melanocyte Protein PMEL)

Beyond the preview

Go deeper on ALVAC gp100 vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALVAC gp100 vaccine.

Explore the full profile